| scholarly article | Q13442814 |
| P50 | author | Elisabet Svenungsson | Q40131460 |
| Daniel Engelbertsen | Q57811480 | ||
| P2093 | author name string | Jan Nilsson | |
| Iva Gunnarsson | |||
| Gunilla Nordin Fredrikson | |||
| Kerstin Elvin | |||
| Johanna T Gustafsson | |||
| Maria Wigren | |||
| Kerstin Jensen-Urstad | |||
| P2860 | cites work | Disturbances of apoptotic cell clearance in systemic lupus erythematosus | Q21195358 |
| Accelerated atherosclerosis in patients with SLE--mechanisms and management | Q26820245 | ||
| Cardiovascular disease in lupus: insights and updates | Q27016554 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease | Q31135767 | ||
| Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis | Q33207408 | ||
| Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. | Q33242507 | ||
| Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study | Q33387473 | ||
| Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays | Q33404418 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients | Q33438663 | ||
| Activation of cultured vascular endothelial cells by antiphospholipid antibodies. | Q33488617 | ||
| Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study | Q33766242 | ||
| B cells and humoral immunity in atherosclerosis | Q33789638 | ||
| Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus | Q33799781 | ||
| Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis | Q33890402 | ||
| High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes | Q33930928 | ||
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus | Q33974685 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| The immune system in atherosclerosis | Q34164644 | ||
| Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus | Q34343906 | ||
| T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein | Q34390132 | ||
| Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus | Q34613997 | ||
| Antibodies to oxidized LDL in atherosclerosis development--clinical and animal studies | Q35888472 | ||
| The role of natural antibodies in atherogenesis | Q36129564 | ||
| Adaptive immunity in atherogenesis: new insights and therapeutic approaches | Q36497196 | ||
| Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus | Q36606667 | ||
| Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease | Q36789663 | ||
| Autoimmunity in atherosclerosis: a protective response losing control? | Q37138017 | ||
| Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. | Q37173369 | ||
| Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes | Q37207913 | ||
| The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? | Q37817582 | ||
| Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases | Q37824302 | ||
| β(2) -Glycoprotein I: evolution, structure and function. | Q37871051 | ||
| Apoptotic cell death and efferocytosis in atherosclerosis | Q37983554 | ||
| Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence | Q38062226 | ||
| Beyond apoptosis in lupus | Q38230898 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Risk factors for cardiovascular disease in systemic lupus erythematosus | Q43767819 | ||
| Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo | Q43882937 | ||
| Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study | Q43885994 | ||
| Premature coronary heart disease in SLE: can we prevent progression? | Q43900414 | ||
| Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations | Q45217508 | ||
| High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction | Q46457217 | ||
| Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice | Q46859383 | ||
| Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. | Q50769120 | ||
| Pattern of arterial calcification in patients with systemic lupus erythematosus. | Q53334388 | ||
| Methodological considerations of ultrasound investigation of intima-media thickness and lumen diameter | Q72815128 | ||
| Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus | Q73167867 | ||
| Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 | ||
| Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events | Q79533802 | ||
| Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study | Q84141759 | ||
| P433 | issue | 3 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| autoantibody | Q785022 | ||
| P304 | page(s) | 417-426 | |
| P577 | publication date | 2015-06-22 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus | |
| P478 | volume | 181 |
| Q59335211 | Associations between circulating IgG antibodies to Apolipoprotein B-derived peptide antigens and acute coronary syndrome in a Chinese Han population |
| Q39123611 | Dyslipidemia in systemic lupus erythematosus |
| Q59791283 | GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis |
| Q37464013 | Interferon (IFN)-λ is a potential mediator in lupus nephritis |
| Q64060940 | MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus |
| Q92820698 | Opportunities for an atherosclerosis vaccine: From mice to humans |
| Q38844782 | Update on cardiovascular disease in lupus |
Search more.